ClinicalTrials.gg

Program

follitropin alfa

Also written as “Gonal-f”, “Follitropin alfa (Primapur)” and “Gonal-f®”.

Its studies are mostly in Infertility · Infertility, Female · Hypogonadism · Anovulation, led by 10 companies.

Furthest: phase 4, since Nov 4, 200523 company-led studies, 3 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany131 open or runningphase 4since Nov 4, 2005Nov 4, 2005Sep 30, 2027phase 3 · NCT07340827
IVFarma20 open or runningphase 3since Mar 2, 2017Mar 2, 2017none ahead
Bharat Serums and Vaccines11 open or runningphase 3since Jan 23, 2022Jan 23, 2022none ahead
Changchun GeneScience Pharmaceutical10 open or runningphase 3since Jan 5, 2015Jan 5, 2015none ahead
Fertility Biotech10 open or runningphase 1since May 19, 2015May 19, 2015none ahead
finox-ag10 open or runningphase 3since May 10, 2010May 10, 2010none ahead
Gema Biotech10 open or runningphase 3since May 22, 2015May 22, 2015none ahead
IBSA Institut Biochimique10 open or runningphase 3since Sep 15, 2006Sep 15, 2006none ahead
MinaPharm Pharmaceuticals10 open or runningphase 4since Nov 30, 2016Nov 30, 2016none ahead
Qilu Pharmaceutical11 open or runningphase 1since Mar 4, 2025Mar 4, 2025none ahead

Also a collaborator on its studies: Merck Serono Middle East FZ, Merck Serono GmbH, Germany, Merck Serono Co., Ltd., Japan and Merck Serono S.P.A., Italy.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Nov 4, 2005.

  1. Dec 20, 2011Phase 3 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT01497197 · 174 enrolled · United Arab Emirates
  2. Jun 4, 2013Phase 4 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT01871532 · 24 enrolled · Ireland, United Kingdom
  3. Jan 5, 2015Changchun GeneScience Pharmaceutical's first study: phase 3 study in AnovulationNew to Changchun GeneScience PharmaceuticalChangchun GeneScience Pharmaceutical · NCT02335879 · 534 enrolled
  4. May 19, 2015Fertility Biotech's first study: phase 1 study in Healthy VolunteersNew to Fertility BiotechFertility Biotech · NCT02459418 · 42 enrolled · United Kingdom
  5. May 22, 2015Gema Biotech's first study: phase 3 study in InfertilityNew to Gema BiotechGema Biotech · NCT02454556 · 106 enrolled · Argentina
  6. Nov 30, 2016MinaPharm Pharmaceuticals's first study: phase 4 study in Infertility, FemaleNew to MinaPharm PharmaceuticalsMinaPharm Pharmaceuticals · NCT03057574 · 200 enrolled · Egypt
  7. Mar 2, 2017IVFarma's first study: phase 3 study in Infertility, FemaleNew to IVFarmaIVFarma · NCT03088137 · 118 enrolled · Russian Federation
  8. Feb 26, 2019Phase 1 study in Area Under CurveIVFarma · NCT03857230 · 28 enrolled · Russian Federation
  9. May 19, 2021Phase 1 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT04899193 · 72 enrolled · China
  10. Jan 23, 2022Bharat Serums and Vaccines's first study: phase 3 study in Infertility, FemaleNew to Bharat Serums and VaccinesBharat Serums and Vaccines · NCT05266924 · 250 enrolled · India
  11. Mar 4, 2025Qilu Pharmaceutical's first study: phase 1 study in Infertility, FemaleNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT06864793 · 48 enrolled · China
  12. Jul 15, 2025Phase 1 study in HypogonadismMerck KGaA, Darmstadt, Germany · NCT07097259 · 55 enrolled · United States
  13. Nov 17, 2025Phase 1 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT07269327 · 24 enrolled · United Kingdom
  14. Jan 6, 2026Phase 3 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT07340827 · 266 planned · Japan

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT07340827

TargetBeta

FSHR →read by rule
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule

Other programs on FSHR

ProgramCompanyFurthest phaseStudies
Follicle Stimulating Hormoneruleglycotope-gmbhphase 46
follitropin deltaruleFerring Pharmaceuticalsphase 318

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07340827Infertility · Japan3RecruitingMerck KGaA, Darmstadt, GermanySep 30, 2027266
NCT07269327Infertility · United Kingdom1CompletedMerck KGaA, Darmstadt, GermanyMar 9, 202624
NCT07097259Hypogonadism · United States1CompletedMerck KGaA, Darmstadt, GermanyDec 23, 202555
NCT06864793Infertility, Female · China1Active, not recruitingQilu PharmaceuticalFeb 4, 202648
NCT05266924Infertility, Female · India3Active, not recruitingBharat Serums and VaccinesAug 31, 2023250
NCT04899193Infertility · China1CompletedMerck KGaA, Darmstadt, GermanyMay 28, 202272
NCT03857230Area Under Curve · Russian Federation1CompletedIVFarmaMay 10, 201628
NCT03088137Infertility, Female · Russian Federation3CompletedIVFarmaAug 17, 2018118
NCT03057574Infertility, Female · Egypt4UNKNOWNMinaPharm PharmaceuticalsDec 2017200
NCT02454556Infertility · Argentina3CompletedGema BiotechDec 2016106
NCT02459418Healthy Volunteers · United Kingdom1CompletedFertility BiotechMay 19, 201642
NCT02335879Anovulation3CompletedChangchun GeneScience PharmaceuticalAug 2009534
NCT01871532Infertility · Ireland, United Kingdom4TerminatedMerck KGaA, Darmstadt, GermanyMar 201424
NCT01497197Infertility · United Arab Emirates3TerminatedMerck KGaA, Darmstadt, GermanyJan 2014174
NCT01183143Infertility · Germany3CompletedMerck KGaA, Darmstadt, GermanyMar 2, 2006215
NCT01185782Infertility · Japan3CompletedMerck KGaA, Darmstadt, GermanyDec 2007300
NCT01121666Infertility · Austria, Denmark, Germany and more3Completedfinox-agDec 2011460
NCT01081626Infertility · Kuwait, Lebanon, Saudi Arabia4CompletedMerck KGaA, Darmstadt, GermanyMar 2011310
NCT01081639Infertility3CompletedMerck KGaA, Darmstadt, GermanySep 200434
NCT01071200Helping Behavior · Italy3TerminatedMerck KGaA, Darmstadt, GermanyApr 2009133
NCT00829244Infertility · Switzerland4CompletedMerck KGaA, Darmstadt, GermanyJan 2010200
NCT00378001Infertility · United States3CompletedIBSA Institut BiochimiqueMay 2006152
NCT00249834Infertility · France4CompletedMerck KGaA, Darmstadt, GermanyJan 16, 2006166

How it is read

Names in the registry

  • “Gonal-f”, 2 entries
  • “Follitropin alfa (Primapur)”, 2 entries
  • “Gonal-f®”, 2 entries
  • “GONAL-f®”, 2 entries
  • “GONAL f® prefilled pen”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.